When HE4 was combined with CA-125 and two other biomarkers, the four-panel set was able to diagnose late-stage ovarian cancer with a sensitivity of 93% and specificity of 98% [65], suggesting the combination is superior to any one biomarker alone. The gene discussed is MUC16; the disease is ovarian carcinoma.